文献速递慢阻肺

罗氟司特对慢阻肺患者动脉僵硬度的随机对照试验

Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial.
PubMed 文献 · Respirology · 2020-07-28

ELASTIC随机安慰剂对照试验纳入80例稳定期慢阻肺患者,罗氟司特或安慰剂治疗24周,主要终点cf-PWV变化两组无显著差异(P=0.268);罗氟司特未改善血管功能或系统性炎症标志物,但6MWT较基线变化显著优于安慰剂(P=0.026)。

要点

  • 罗氟司特24周未显著改善慢阻肺患者cf-PWV。
  • 血管功能及系统性炎症标志物均未见改善。
  • 罗氟司特组6MWT较基线变化显著优于安慰剂。

核心结论

  • 罗氟司特对稳定期慢阻肺患者动脉僵硬度无有益效应。
  • 需进一步研究验证罗氟司特对运动耐量的潜在改善。

研究设计与样本

  • 随机安慰剂对照试验,80例稳定期慢阻肺患者接受罗氟司特或安慰剂治疗24周。
  • 完成罗氟司特组33例、安慰剂组34例;年龄中位数(IQR)64.5(61-69.5)vs 64.5(56-72)岁。
  • FEV1中位数(IQR)34.5(25.5-48.6)vs 35.3(27-46.8)%预计值;6MWT中位数(IQR)428(340-558)vs 456(364-570)m。

主要发现

  • cf-PWV较基线变化罗氟司特组+5.0%(95%CI:-2.0至+13.0)vs 安慰剂组0.0%(95%CI:-7.0至+7.0),P=0.268。
  • 罗氟司特未改善血管功能标志物或系统性炎症标志物。
  • 6MWT较基线变化罗氟司特组+53.0(95%CI:+19.1至+86.9)m vs 安慰剂组-0.92(95%CI:-35.1至+33.3)m,P=0.026。

临床怎么用

  • 罗氟司特不应以改善动脉僵硬度为目的用于稳定期慢阻肺患者。
  • 罗氟司特对运动耐量的潜在获益需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Cardiovascular risk is substantially increased in patients with COPD and can be quantified via arterial stiffness. The PDE-IV inhibitor roflumilast revealed a potential reduction of COPD-related cardiovascular risk. We aimed to investigate the effects of roflumilast on arterial stiffness by quantification of pulse wave velocity (PWV) in stable COPD. METHODS: In this randomized placebo-controlled trial, 80 COPD patients received roflumilast or placebo for 24 weeks. The primary outcome was the change in cf-PWV. Secondary outcomes comprised markers of vascular function (e.g. Aix and RHI), systemic inflammation (e.g. IL-6 and TNF-α) and clinical characteristics of COPD (e.g. CAT and 6MWT). RESULTS: A total of 33 and 34 patients completed the roflumilast and placebo arm, respectively (age, median (IQR): 64.5 (61-69.5) vs 64.5 (56-72) years; FEV1 , median (IQR): 34.5 (25.5-48.6) vs 35.3 (27-46.8) % predicted; 6MWT, median (IQR): 428 (340-558) vs 456 (364-570) m). Change from baseline PWV did not show a significant difference between roflumilast and placebo (+5.0 (95% CI: -2.0 to +13.0) vs 0.0 (95% CI: -7.0 to +7.0)%, P = 0.268). Roflumilast did not improve markers of vascular function or systemic inflammation. We observed a significant improvement in change from baseline 6MWT with roflumilast versus placebo (+53.0 (95% CI: +19.1 to +86.9) vs -0.92 (95% CI: -35.1 to +33.3) m, P = 0.026). CONCLUSION: Our study revealed no beneficial effects of roflumilast on arterial stiffness. Further studies are needed to test a potential improvement of exercise capacity with roflumilast in COPD.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Urban MH, Kreibich N, Gleiss A, et al. Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial. Respirology. 2020. PMID: 32725799. doi:10.1111/resp.13914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。